Menu

Immunotherapy Promising for Diabetes: Study

A small clinical trial demonstrates that peptide immunotherapy can halt the progression of early-stage type 1 diabetes.

Aug 9, 2017
Aggie Mika

Simplified schematic of peptide immunotherapy for type 1 diabetes

CARLA SCHAFFER, AAAS, ALI ET AL., SCI TRANS MED, 9:EAAF7779, 2017

  

For the first time, scientists demonstrate that immunotherapy can safely stabilize the progression of early-stage type 1 diabetes in a trial of 27 individuals, according to a report published today (August 9) in Science Translational Medicine.

“The fact that this small study, designed to assess safety, suggests there may be a beneficial outcome is exciting, as we desperately need safe immune interventions that can prevent the decline of the patient’s own insulin secretion in type 1 diabetes,” Andrew Hattersley of the University of Exeter, who was not an author of the study, tells New Scientist.

Type 1 diabetes is an autoimmune disorder in which the immune system mistakenly targets and destroys insulin-producing pancreatic beta cells. While administering insulin can manage the disorder, it doesn’t halt disease progression and, as the authors note in their report, can’t completely protect patients from bouts of extreme dips and peaks in blood sugar, which shorten lifespans and lead to other devastating consequences.

Peptide immunotherapy, a form of antigen-specific immunotherapy, is based on the premise that small protein fragments resembling the very antigens that are targeted in an autoimmune disease can work to dampen immune responses to that antigen. These truncated peptides can prompt certain regulatory T cells into action, quelling these over-active responses by inflammatory T cells. 

Here, researchers used a proinsulin peptide fragment—a snippet of the precursor form of insulin. Twenty-seven people with early-stage type 1 diabetes were randomly assigned to receive the placebo or the proinsulin peptide immunotherapy. Subjects in the immunotherapy group were further split into high-frequency or low-frequency injections, in which they either received the peptide every two weeks or every four weeks for six months, then were observed for six months following the therapy.

Participants receiving the immunotherapy did not need to increase their insulin dose, unlike their placebo counterparts, demonstrating that the therapy allowed them to stabilize. Furthermore, the patients demonstrated signs of increased regulatory immune responses, and decreased activation of beta cell-attacking T cells.

While promising, these results will need to be repeated in a larger trial, the authors write in their report.

“We’re looking at a drug that could be usable in five to 10 years, if everything goes well,” coauthor Mark Peakman of King’s College London tells New Scientist

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.